相似文献
1
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
Cancer. 2021 Apr 1;127(7):1010-1020. doi: 10.1002/cncr.33433. Epub 2021 Feb 23.
2
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2.
3
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Drugs. 2021 Jun;81(9):971-984. doi: 10.1007/s40265-021-01506-0. Epub 2021 Jun 9.
4
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
PLoS One. 2024 Jul 15;19(7):e0307204. doi: 10.1371/journal.pone.0307204. eCollection 2024.
5
Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
EBioMedicine. 2020 Dec;62:103040. doi: 10.1016/j.ebiom.2020.103040. Epub 2020 Nov 7.
6
Nivolumab plus ipilimumab in malignant pleural mesothelioma.
Expert Rev Anticancer Ther. 2022 Aug;22(8):815-822. doi: 10.1080/14737140.2022.2102482. Epub 2022 Jul 25.
7
[New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
Bull Cancer. 2022 Jan;109(1):4-6. doi: 10.1016/j.bulcan.2021.07.010. Epub 2021 Oct 13.
8
Breaking through the treatment desert of conventional mesothelin-targeted CAR-T cell therapy for malignant mesothelioma: A glimpse into the future.
Pharmacol Res. 2024 Jun;204:107220. doi: 10.1016/j.phrs.2024.107220. Epub 2024 May 18.
9
Nivolumab for the treatment of unresectable pleural mesothelioma.
Expert Opin Biol Ther. 2020 Feb;20(2):109-114. doi: 10.1080/14712598.2020.1703945. Epub 2019 Dec 16.
10
True Benefits of Immune Checkpoint Inhibitors in the Treatment of Malignant Pleural Mesothelioma in Japan.
Anticancer Res. 2024 Oct;44(10):4135-4145. doi: 10.21873/anticanres.17244.
引用本文的文献
1
Successful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma: Two Case Reports.
Case Rep Oncol. 2025 Jan 30;18(1):278-285. doi: 10.1159/000543889. eCollection 2025 Jan-Dec.
2
Thermosensitive Resiquimod-Loaded Lipid Nanoparticles Promote the Polarization of Tumor-Associated Macrophages to Enhance Bladder Cancer Immunotherapy.
ACS Nano. 2025 Jun 3;19(21):19599-19621. doi: 10.1021/acsnano.4c17444. Epub 2025 May 17.
3
Bidirectional Mendelian randomization and potential mechanistic insights into the causal relationship between gut microbiota and malignant mesothelioma.
Medicine (Baltimore). 2025 Apr 25;104(17):e42245. doi: 10.1097/MD.0000000000042245.
4
Capsaicin Exerts Antitumor Activity in Mesothelioma Cells.
Nutrients. 2024 Nov 1;16(21):3758. doi: 10.3390/nu16213758.
5
The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.
J Cancer Metastasis Treat. 2023;9. doi: 10.20517/2394-4722.2022.140. Epub 2023 May 30.
6
Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990-2019.
J Cancer Res Clin Oncol. 2024 May 28;150(5):282. doi: 10.1007/s00432-024-05802-6.
7
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.
Mol Cancer. 2024 Apr 16;23(1):77. doi: 10.1186/s12943-024-01956-6.
8
Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies.
Int J Nanomedicine. 2024 Jan 20;19:633-650. doi: 10.2147/IJN.S435787. eCollection 2024.
9
Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma.
Radiother Oncol. 2024 Feb;191:110057. doi: 10.1016/j.radonc.2023.110057. Epub 2023 Dec 15.
10
Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review.
Front Oncol. 2023 Apr 21;13:1156329. doi: 10.3389/fonc.2023.1156329. eCollection 2023.
本文引用的文献
1
FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
Oncology (Williston Park). 2020 Nov 12;34(11):502-503. doi: 10.46883/ONC.2020.3411.0502.
2
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Ann Oncol. 2020 Dec;31(12):1734-1745. doi: 10.1016/j.annonc.2020.09.009. Epub 2020 Sep 22.
3
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Cancer. 2020 Nov 15;126(22):4936-4947. doi: 10.1002/cncr.33145. Epub 2020 Sep 1.
4
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
Sci Transl Med. 2020 Jul 1;12(550). doi: 10.1126/scitranslmed.aaz7252.
5
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Front Oncol. 2020 Mar 12;10:343. doi: 10.3389/fonc.2020.00343. eCollection 2020.
6
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
J Clin Oncol. 2020 Jun 1;38(16):1824-1835. doi: 10.1200/JCO.19.02085. Epub 2020 Mar 26.
7
Peritoneal mesothelioma.
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S120-S132. doi: 10.21037/tlcr.2019.12.15.
8
Nivolumab for the treatment of unresectable pleural mesothelioma.
Expert Opin Biol Ther. 2020 Feb;20(2):109-114. doi: 10.1080/14712598.2020.1703945. Epub 2019 Dec 16.
9
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Mol Ther. 2019 Nov 6;27(11):1919-1929. doi: 10.1016/j.ymthe.2019.07.015. Epub 2019 Jul 30.
10
Clinical Efficacy and Safety of Nivolumab: Results of a ulticenter, Opn-label, Single-am, Japanese Phase II study in Malgnant Pleural Mesohelioma (MERIT).
Clin Cancer Res. 2019 Sep 15;25(18):5485-5492. doi: 10.1158/1078-0432.CCR-19-0103. Epub 2019 Jun 4.
Zotero 插件